Search

Memorial Sloan Kettering (MSK) has reached a major milestone in bringing personalized treatments to more cancer patients. Michael Berger, PhD, Ahmet Zehir, PhD, and colleagues have reported an in-depth analysis of the first 10,336 patients whose tumors were submitted for clinical genomic sequencing by MSK-IMPACT™, a powerful diagnostic test developed at MSK to provide detailed genetic information about a patient’s cancer.

… Monday, May 8, 2017 Memorial Sloan Kettering (MSK) has reached a major milestone in bringing personalized treatments to more cancer patients. Michael Berger, PhD , Ahmet Zehir, PhD, and colleagues have reported an in-depth analysis of the first 10,336 patients whose tumors were submitted for clinical

Chemotherapy after immune checkpoint inhibitors (ICIs) may improve survival rates in patients with heavily pretreated, recurrent ovarian cancer.

… Thursday, September 19, 2019 Chemotherapy after immune checkpoint inhibitors (ICIs) may improve survival rates in patients with heavily pretreated, recurrent ovarian cancer, according to our retrospective review of outcomes for 79 women treated at Memorial Sloan Kettering Cancer Center. Median overall

Molecular biologist Christine Mayr, MD, PhD, of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) is one of 12 2016 recipients of the prestigious National Institutes of Health (NIH) Director’s Pioneer Award. Established in 2004, the annual award recognizes and supports individual scientists of exceptional creativity who propose pioneering and highly innovative approaches with the potential to produce an unusually high impact on biomedical or behavioral research.

… Tuesday, October 4, 2016 Molecular biologist Christine Mayr, MD, PhD , of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) is one of 12 2016 recipients of the prestigious National Institutes of Health (NIH) Director’s Pioneer Award. Established in 2004, the annual award recognizes and

New MSK research investigates whether introducing new mutations could make immunotherapy more effective against some cancers; shows that people in their 90s who underwent lung cancer surgery had positive outcomes; shares lessons on the responsible governance of artificial intelligence in oncology; studies AI-assisted biomarker assessment in lung cancer; and demonstrates a cancer-trained large language model has strong predictive value.

… Tuesday, July 15, 2025 New research from Memorial Sloan Kettering Cancer Center (MSK) investigates whether introducing new mutations could make immunotherapy more effective against some cancers; shows that people in their 90s who underwent lung cancer surgery had positive outcomes; shares lessons on

Early-onset colorectal cancer (CRC) is likely clinically and genomically indistinguishable from average-onset cancer, according to a recent study published in the Journal of the National Cancer Institute by MSK investigators.

… Monday, September 13, 2021 Early-onset colorectal cancer (CRC) is likely clinically and genomically indistinguishable from average-onset cancer, according to a recent study published in the Journal of the National Cancer Institute by MSK investigators.The findings suggest that aggressive treatment for

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments.

… Tuesday, June 21, 2022 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Alban Ordureau Selected into the 2022 Class of Pew Scholars in Biomedical Sciences Alban Ordureau, PhD Alban Ordureau, PhD , has been selected into the 2022 class of Pew Scholars in Biomedical

Memorial Sloan Kettering investigators have shown that a new type of cancer vaccine might be more effective than previous therapies at inducing immune cells to destroy tumors.

… Tuesday, December 1, 2009 Summary Memorial Sloan Kettering investigators have shown that a new type of cancer vaccine might be more effective than previous therapies at inducing immune cells to destroy tumors. Memorial Sloan Kettering investigators have shown that a new type of cancer vaccine might be

People with prostate cancer can benefit from exercise in more ways than they might expect.

… Thursday, September 24, 2020 Summary Treatments for prostate cancer can cause side effects such as loss of muscle mass and fatigue.  Finding the time and energy to exercise is difficult for many people. For men diagnosed with prostate cancer, it can be especially challenging because treatments often

Learn how Dr. Chrysothemis Brown is shedding light on new types of immune cells and their role in cancer and other diseases.

… Tuesday, November 7, 2023 When physician-scientist Chrysothemis Brown, MBBS, PhD , talks about the process of scientific discovery and the nuances of the immune system, the sincerity of her enthusiasm is unmistakable. “What I love about science is the freedom and creativity,” Dr. Brown says. “And if

Louis V. Gerstner, Jr. makes a generous $25 million commitment to establish the Louis V. Gerstner, Jr. Physician Scholars Program.

… Wednesday, September 29, 2021 Memorial Sloan Kettering Cancer Center (MSK) today announced a $25 million gift from Louis V. Gerstner, Jr. to create the Louis V. Gerstner, Jr. Physician Scholars Program . Designed to support the innovative research of physician-scientists who are early in their career